Omnicell, Inc.
OMCL
Electronic Computers
Mkt Cap
$1.482BPE
-70.40Debt
$570.4MCash
$550MEV
$1.502BFCF
$178MP/E Ratio
-70.40Debt
$570.4MCash
$550MEV
$1.502BFCF
$178MCharts data: {"Earnings":[{"time":"2014-12-30","value":30518000},{"time":"2015-12-30","value":30760000},{"time":"2016-12-30","value":603000},{"time":"2017-12-30","value":20605000},{"time":"2018-12-30","value":37729000},{"time":"2019-12-30","value":61338000},{"time":"2020-12-30","value":32194000},{"time":"2021-12-30","value":77849000},{"time":"2022-12-30","value":5648000},{"time":"2023-12-30","value":-20371000}],"Sales":[{"time":"2014-12-30","value":440900000},{"time":"2015-12-30","value":484559000},{"time":"2016-12-30","value":692623000},{"time":"2017-12-30","value":716165000},{"time":"2018-12-30","value":787309000},{"time":"2019-12-30","value":897027000},{"time":"2020-12-30","value":892208000},{"time":"2021-12-30","value":1132018000},{"time":"2022-12-30","value":1295947000},{"time":"2023-12-30","value":1147112000}],"Net Margins":[{"time":"2014-12-30","value":0.06921750963937401},{"time":"2015-12-30","value":0.06348040176738023},{"time":"2016-12-30","value":0.0008706034884778588},{"time":"2017-12-30","value":0.02877130270258949},{"time":"2018-12-30","value":0.047921464126537354},{"time":"2019-12-30","value":0.06837921266583949},{"time":"2020-12-30","value":0.03608351415813353},{"time":"2021-12-30","value":0.06877010789581084},{"time":"2022-12-30","value":0.0043582029203354765},{"time":"2023-12-30","value":-0.01775851006702048}],"Assets":[{"time":"2014-12-30","value":560214000},{"time":"2015-12-30","value":578747000},{"time":"2016-12-30","value":935103000},{"time":"2017-12-30","value":980304000},{"time":"2018-12-30","value":1081242000},{"time":"2019-12-30","value":1240810000},{"time":"2020-12-30","value":1824504000},{"time":"2021-12-30","value":2142496000},{"time":"2022-12-30","value":2210758000},{"time":"2023-12-30","value":2226878000}],"Stockholders Equity":[{"time":"2014-12-30","value":390098000},{"time":"2015-12-30","value":402388000},{"time":"2016-12-30","value":431607000},{"time":"2017-12-30","value":517199000},{"time":"2018-12-30","value":679617000},{"time":"2019-12-30","value":845254000},{"time":"2020-12-30","value":967503000},{"time":"2021-12-30","value":1146689000},{"time":"2022-12-30","value":1130137000},{"time":"2023-12-30","value":1188954000}],"ROE":[{"time":"2014-12-30","value":0.07823162384836631},{"time":"2015-12-30","value":0.07644363151982664},{"time":"2016-12-30","value":0.0013971043101710585},{"time":"2017-12-30","value":0.03983959752435716},{"time":"2018-12-30","value":0.055515091588350496},{"time":"2019-12-30","value":0.07256753591228199},{"time":"2020-12-30","value":0.03327534901700563},{"time":"2021-12-30","value":0.06789024748645885},{"time":"2022-12-30","value":0.004997624181846979},{"time":"2023-12-30","value":-0.017133547639353583}],"ROA":[{"time":"2014-12-30","value":0.08850724901555478},{"time":"2015-12-30","value":0.08402980922579296},{"time":"2016-12-30","value":0.006930787303644625},{"time":"2017-12-30","value":0.0058696077951329384},{"time":"2018-12-30","value":0.041056488741650805},{"time":"2019-12-30","value":0.06314584827652904},{"time":"2020-12-30","value":0.01947159337551466},{"time":"2021-12-30","value":0.04177697414604275},{"time":"2022-12-30","value":-0.0010507708215915085},{"time":"2023-12-30","value":-0.009029681913423187}]}
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.
DCF
Discounted Cash Flow Valuation of Omnicell, Inc.
Value
Growth
%
%
Discount
%
%
Multiple
| g\r | +10% | +11% | +12% | +13% | +14% |
|---|---|---|---|---|---|
| 0% | 10 | 9 | 8 | 8 | 7 |
| +1% | 11 | 10 | 9 | 8 | 8 |
| +2% | 13 | 11 | 10 | 9 | 8 |
| +3% | 14 | 13 | 11 | 10 | 9 |
| +4% | 17 | 14 | 12 | 11 | 10 |
| Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF | $178M | $219.9M | $267.2M | $319.2M | $374.6M | $432M | $489.2M | $543.9M | $593.6M | $635.5M | $667.3M | $6.673B |
| DCF | $191.2M | $202.1M | $209.8M | $214.2M | $214.8M | $211.5M | $204.5M | $194M | $180.6M | $164.9M | $1.649B | |
| Value | $3.637B | |||||||||||
In the chart Earnings are multiplied by this value.
Earnings Growth 18%
Earnings Stability -9.2%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 6.3% | 0.087% | 2.9% | 4.8% | 6.8% | 3.6% | 6.9% | 0.44% | -1.8% | -1.9% |
| ROA | 8.4% | 0.69% | 0.59% | 4.1% | 6.3% | 1.9% | 4.2% | -0.11% | -0.9% | -0.73% |
| ROE | 7.6% | 0.14% | 4% | 5.6% | 7.3% | 3.3% | 6.8% | 0.5% | -1.7% | -1.8% |
What is the average Net Margin?
The average Net Margin over the past 5 years is +3.46%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -1.39%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is +2.59%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -1.2%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is +3.62%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -1.52%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | 0.00 | 7.37 | 22.13 | 1.74 | 0.39 | 2.87 | 2.41 | 18.73 | 4.08 | 3.20 |
| Debt Equity | 0.00 | 0.59 | 0.41 | 0.21 | 0.06 | 0.48 | 0.43 | 0.50 | 0.48 | 0.48 |
| MIN | ||||||||||
| Graham Stability | - | - | 100% | 100% | 100% | 81% | 100% | 9.9% | -53% | -53% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is 3.20.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is 1.89.
What is the Graham’s Stability?
Graham’s Stability measure stands at -0.53.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 7.5% | 7.8% | 8.7% | -11% | -2.2% |
| Net Income | - | - | - | - | -110% |
| Stockholders Equity | 16% | 12% | 7.1% | 5.2% | -0.62% |
| FCF | 22% | 12% | -5% | 360% | 13% |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +7.82%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -2.24%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -113.93%.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +11.84%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -0.62%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +11.71%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is +12.9%.